Illegal Drugs Laws: Clearing a 50-Year-Old Obstacle to Research

For over 50 years, many medical drugs have been effectively banned from research and clinical treatment in the vain hope that this will stop recreational use. The scientific community should now challenge this pointless ban and get governments to improve their regulations so science can flourish.

[1]  S. Schreiber,et al.  The intriguing effects of ecstasy (MDMA) on cognitive function in mice subjected to a minimal traumatic brain injury (mTBI) , 2011, Psychopharmacology.

[2]  R. Pertwee.  Handbook of Cannabis , 2014 .

[3]  T. Passie,et al.  Safety and Efficacy of Lysergic Acid Diethylamide-Assisted Psychotherapy for Anxiety Associated With Life-threatening Diseases , 2014, The Journal of nervous and mental disease.

[4]  C. Grob,et al.  Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. , 2011, Archives of general psychiatry.

[5]  Richard G. Wise,et al.  Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin , 2012, Proceedings of the National Academy of Sciences.

[6]  P. Celada,et al.  The natural hallucinogen 5-MeO-DMT, component of Ayahuasca, disrupts cortical function in rats: reversal by antipsychotic drugs. , 2014, The international journal of neuropsychopharmacology.

[7]  H. Pope,et al.  Response of cluster headache to psilocybin and LSD , 2006, Neurology.

[8]  Matthew W. Johnson,et al.  Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction , 2014, Journal of psychopharmacology.

[9]  P. Delgado,et al.  Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. , 2006, The Journal of clinical psychiatry.

[10]  M. Coppola,et al.  Methoxetamine: from drug of abuse to rapid-acting antidepressant. , 2012, Medical hypotheses.

[11]  J. Brotchie,et al.  Characterization of 3,4-Methylenedioxymethamphetamine (MDMA) Enantiomers In Vitro and in the MPTP-Lesioned Primate: R-MDMA Reduces Severity of Dyskinesia, Whereas S-MDMA Extends Duration of ON-Time , 2011, The Journal of Neuroscience.

[12]  T. S. Krebs,et al.  Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials , 2012, Journal of psychopharmacology.

[13]  T. Brewerton,et al.  Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: a prospective long-term follow-up study , 2013, Journal of psychopharmacology.

[14]  J. Juillard,et al.  [Parkinson disease]. , 1985, Revue de l'infirmiere.

[15]  H. Emrich,et al.  Mitigation of post-traumatic stress symptoms by Cannabis resin: a review of the clinical and neurobiological evidence. , 2012, Drug testing and analysis.

[16]  M. Rowbotham,et al.  Cannabis in painful HIV-associated sensory neuropathy , 2007, Neurology.

[17]  D. E. Nichols,et al.  Effects of Schedule I drug laws on neuroscience research and treatment innovation , 2013, Nature Reviews Neuroscience.

[18]  G. Skopp,et al.  Cannabis improves symptoms of ADHD , 2008 .

[19]  J. Hobart,et al.  MUltiple Sclerosis and Extract of Cannabis: results of the MUSEC trial , 2012, Journal of Neurology, Neurosurgery & Psychiatry.

[20]  Matthew W. Johnson,et al.  Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later , 2008, Journal of psychopharmacology.